Logo image of PHAT

PHATHOM PHARMACEUTICALS INC (PHAT) Stock Fundamental Analysis

USA - NASDAQ:PHAT - US71722W1071 - Common Stock

13.31 USD
-0.22 (-1.63%)
Last: 10/30/2025, 6:34:06 PM
13.6 USD
+0.29 (+2.18%)
After Hours: 10/30/2025, 6:34:06 PM
Fundamental Rating

2

Overall PHAT gets a fundamental rating of 2 out of 10. We evaluated PHAT against 192 industry peers in the Pharmaceuticals industry. PHAT may be in some trouble as it scores bad on both profitability and health. PHAT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PHAT has reported negative net income.
In the past year PHAT has reported a negative cash flow from operations.
PHAT had negative earnings in each of the past 5 years.
PHAT had a negative operating cash flow in each of the past 5 years.
PHAT Yearly Net Income VS EBIT VS OCF VS FCFPHAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -131.95%, PHAT is not doing good in the industry: 82.29% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -131.95%
ROE N/A
ROIC N/A
ROA(3y)-85.69%
ROA(5y)-75.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PHAT Yearly ROA, ROE, ROICPHAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

With an excellent Gross Margin value of 86.91%, PHAT belongs to the best of the industry, outperforming 91.15% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for PHAT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHAT Yearly Profit, Operating, Gross MarginsPHAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

More info and screens

2

2. Health

2.1 Basic Checks

PHAT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PHAT has more shares outstanding
Compared to 5 years ago, PHAT has more shares outstanding
Compared to 1 year ago, PHAT has a worse debt to assets ratio.
PHAT Yearly Shares OutstandingPHAT Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PHAT Yearly Total Debt VS Total AssetsPHAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -9.62, we must say that PHAT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.62, PHAT is not doing good in the industry: 68.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.62
ROIC/WACCN/A
WACC7.99%
PHAT Yearly LT Debt VS Equity VS FCFPHAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

PHAT has a Current Ratio of 2.38. This indicates that PHAT is financially healthy and has no problem in meeting its short term obligations.
PHAT has a Current ratio (2.38) which is in line with its industry peers.
PHAT has a Quick Ratio of 2.35. This indicates that PHAT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.35, PHAT is in line with its industry, outperforming 48.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.38
Quick Ratio 2.35
PHAT Yearly Current Assets VS Current LiabilitesPHAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

PHAT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.80%.
Looking at the last year, PHAT shows a very strong growth in Revenue. The Revenue has grown by 1049.81%.
EPS 1Y (TTM)7.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
Revenue 1Y (TTM)1049.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%439.36%

3.2 Future

The Earnings Per Share is expected to grow by 24.51% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 76.32% on average over the next years. This is a very strong growth
EPS Next Y37.6%
EPS Next 2Y35.25%
EPS Next 3Y30.77%
EPS Next 5Y24.51%
Revenue Next Year236.42%
Revenue Next 2Y153.76%
Revenue Next 3Y115.62%
Revenue Next 5Y76.32%

3.3 Evolution

PHAT Yearly Revenue VS EstimatesPHAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PHAT Yearly EPS VS EstimatesPHAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHAT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHAT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHAT Price Earnings VS Forward Price EarningsPHAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHAT Per share dataPHAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

PHAT's earnings are expected to grow with 30.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.25%
EPS Next 3Y30.77%

More info and screens

0

5. Dividend

5.1 Amount

PHAT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PHATHOM PHARMACEUTICALS INC

NASDAQ:PHAT (10/30/2025, 6:34:06 PM)

After market: 13.6 +0.29 (+2.18%)

13.31

-0.22 (-1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners65.5%
Inst Owner Change-0.35%
Ins Owners1.99%
Ins Owner Change1.93%
Market Cap944.21M
Revenue(TTM)114.04M
Net Income(TTM)-330154000
Analysts84
Price Target21.8 (63.79%)
Short Float %25.62%
Short Ratio12.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.49%
Min EPS beat(2)-12%
Max EPS beat(2)1.02%
EPS beat(4)3
Avg EPS beat(4)5.38%
Min EPS beat(4)-12%
Max EPS beat(4)19.05%
EPS beat(8)4
Avg EPS beat(8)-0.72%
EPS beat(12)8
Avg EPS beat(12)3.85%
EPS beat(16)10
Avg EPS beat(16)1.41%
Revenue beat(2)1
Avg Revenue beat(2)1.86%
Min Revenue beat(2)-3.64%
Max Revenue beat(2)7.35%
Revenue beat(4)3
Avg Revenue beat(4)11.9%
Min Revenue beat(4)-3.64%
Max Revenue beat(4)27.14%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.55%
EPS NQ rev (1m)1.8%
EPS NQ rev (3m)16.15%
EPS NY rev (1m)-0.81%
EPS NY rev (3m)5.37%
Revenue NQ rev (1m)1.04%
Revenue NQ rev (3m)9%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)6.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.28
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.73
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)-3.87
FCFYN/A
OCF(TTM)-3.87
OCFYN/A
SpS1.61
BVpS-5.72
TBVpS-5.72
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -131.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.91%
FCFM N/A
ROA(3y)-85.69%
ROA(5y)-75.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.37%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.38
Quick Ratio 2.35
Altman-Z -9.62
F-Score3
WACC7.99%
ROIC/WACCN/A
Cap/Depr(3y)156.3%
Cap/Depr(5y)171.47%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%32.69%
EPS Next Y37.6%
EPS Next 2Y35.25%
EPS Next 3Y30.77%
EPS Next 5Y24.51%
Revenue 1Y (TTM)1049.81%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%439.36%
Revenue Next Year236.42%
Revenue Next 2Y153.76%
Revenue Next 3Y115.62%
Revenue Next 5Y76.32%
EBIT growth 1Y-6.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.81%
EBIT Next 3Y37.46%
EBIT Next 5Y31.42%
FCF growth 1Y-98.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-99.15%
OCF growth 3YN/A
OCF growth 5YN/A

PHATHOM PHARMACEUTICALS INC / PHAT FAQ

What is the ChartMill fundamental rating of PHATHOM PHARMACEUTICALS INC (PHAT) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PHAT.


Can you provide the valuation status for PHATHOM PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to PHATHOM PHARMACEUTICALS INC (PHAT). This can be considered as Overvalued.


Can you provide the profitability details for PHATHOM PHARMACEUTICALS INC?

PHATHOM PHARMACEUTICALS INC (PHAT) has a profitability rating of 1 / 10.


What is the financial health of PHATHOM PHARMACEUTICALS INC (PHAT) stock?

The financial health rating of PHATHOM PHARMACEUTICALS INC (PHAT) is 2 / 10.


What is the expected EPS growth for PHATHOM PHARMACEUTICALS INC (PHAT) stock?

The Earnings per Share (EPS) of PHATHOM PHARMACEUTICALS INC (PHAT) is expected to grow by 37.6% in the next year.